The UK healthtech firm won the funding as part of the 43North startup competition and the People's Choice Award.
"We are so proud to have received the recent funding from 43North, and to have also been recognised by the Buffalo community for the People's Choice Award."
The oversubscribed round will scale automated laboratories and molecular design operations.
"Chemify aims to become the global digital backbone of chemistry, enabling fast design and discovery. Our vision is that Chemify will be able to design and make any molecule on demand for our customers across all of chemistry from drug discovery to new catalysts and electronic materials. The next step in our evolution is nothing short of a revolution in the digitization and automation of chemical discovery and manufacturing."
TwinPath Ventures led the pre-seed round to help accelerate regulatory clearance and clinical validation for the company's sepsis prediction software.
"I’ve lived through sepsis twice. I know how quickly stability becomes a crisis and how much an earlier insight can change the outcome. With VIOSync we’re giving clinicians a trusted, explainable way to predict risk before symptoms emerge, enabling faster decisions and ultimately saving lives. This funding is a strong validation of our mission and will help us accelerate both regulatory approvals and clinical adoption."
The financing round was led by SV Health Investors and will fund initial human trials for the company lead candidate in ALS and Parkinson's.
"Developing new drugs to treat neurological diseases is very challenging, but is receiving increased interest given the high unmet medical need and growing prevalence in ageing populations."